Cartesian Therapeutics (RNAC) jumped over 30% on Tuesday after announcing a licensing deal to develop its CAR-T cell ...

Cartesian Therapeutics, Inc. RNAC stock is up on Tuesday as the company is announcing a strategic licensing agreement with ...

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans ...

Shares of Cartesian Therapeutics rose in premarket trading Tuesday after the company struck a deal to use WestGene Biopharma's lipid-nanoparticle delivery technology for its therapies for autoimmune ...

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune ...

So, the natural question for Cartesian Therapeutics (NASDAQ:RNAC) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual ...

Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian’s financial ...

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.

Just to go ahead and give everyone a quick refresher, CAR-T treatment aims to reengineer a patient’s T-cells so that they will eliminate harmful B-cells that cause all sorts of problems. To this day, ...

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...